3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
3
Urinary Bladder Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancer
1
Interventions
Irinotecan
30
Paclitaxel
24
Gemcitabine
21
Cisplatin
21
Docetaxel
19
Fluorouracil
15
alvocidib
12
Oxaliplatin
11
Leucovorin
11
Carboplatin
11
Capecitabine
11
Bortezomib
9
Taxes
8
Topotecan
7
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
7
Vorinostat
6
Immunohistochemistry
6
tanespimycin
5
Temozolomide
5
Sorafenib
5
Pemetrexed
5
Early Intervention, Educational
5
Chromatography, High Pressure Liquid
5
Bevacizumab
5
7-hydroxystaurosporine
5
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
5
ixabepilone
4
bryostatin 1
4
Sirolimus
4
Pharmacogenomic Testing
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Unspecified Adult Solid Tumor, Protocol Specific
×
bempegaldesleukin
×
Clear all
NCT02869295
2021-07-29
NKTR-214
Nektar Therapeutics
Phase 1/2
Completed
28 enrolled
16 charts